Tags

Type your tag names separated by a space and hit enter

The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma.
Am Rev Respir Dis 1989; 139(2):463-9AR

Abstract

Inhaled adenosine and adenosine 5'-monophosphate (AMP) cause bronchoconstriction in atopic and nonatopic asthmatics by a mechanism believed to involve histamine release from airway mast cells and an interaction with neural reflexes. In the present study, we have investigated the effect of oral terfenadine 180 mg, flurbiprofen 100 mg, and the drug combination on AMP-induced bronchoconstriction in eight nonatopic asthmatic subjects with a mean age of 53.8 +/- 5.6 yr. The provocation concentrations of histamine and AMP required to produce a 20% decrease in FEV1 (PC20) were determined to be 2.5 (range, 0.2 to 16.3) and 50.1 (range, 1.5 to 841) mg/ml, respectively, representing a potency difference of 17.8-fold on a molar basis. In subsequent time-course studies, the bronchoconstrictor response to inhalation of the PC20 histamine was suppressed completely by terfenadine and the drug combination, but unaffected by flurbiprofen. Terfenadine alone and flurbiprofen alone inhibited bronchoconstriction provoked by the PC20 AMP by 49.8 +/- 5.5% (p less than 0.01) and 31.9 +/- 7.9% (p less than 0.01), respectively, when areas under the FEV1 time curves were compared with placebo, the difference between the two treatments not being significant (p = 0.06). The drug combination inhibited the response to AMP by 60.0 +/- 8.3% (p less than 0.01), this being significantly greater than with flurbiprofen (p less than 0.01), but not with terfenadine alone. These data implicate both histamine and cyclooxygenase products in the bronchoconstrictor response to AMP.

Authors+Show Affiliations

Southampton General Hospital, United Kingdom.No affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2563320

Citation

Phillips, G D., and S T. Holgate. "The Effect of Oral Terfenadine Alone and in Combination With Flurbiprofen On the Bronchoconstrictor Response to Inhaled Adenosine 5'-monophosphate in Nonatopic Asthma." The American Review of Respiratory Disease, vol. 139, no. 2, 1989, pp. 463-9.
Phillips GD, Holgate ST. The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma. Am Rev Respir Dis. 1989;139(2):463-9.
Phillips, G. D., & Holgate, S. T. (1989). The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma. The American Review of Respiratory Disease, 139(2), pp. 463-9.
Phillips GD, Holgate ST. The Effect of Oral Terfenadine Alone and in Combination With Flurbiprofen On the Bronchoconstrictor Response to Inhaled Adenosine 5'-monophosphate in Nonatopic Asthma. Am Rev Respir Dis. 1989;139(2):463-9. PubMed PMID: 2563320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma. AU - Phillips,G D, AU - Holgate,S T, PY - 1989/2/1/pubmed PY - 1989/2/1/medline PY - 1989/2/1/entrez SP - 463 EP - 9 JF - The American review of respiratory disease JO - Am. Rev. Respir. Dis. VL - 139 IS - 2 N2 - Inhaled adenosine and adenosine 5'-monophosphate (AMP) cause bronchoconstriction in atopic and nonatopic asthmatics by a mechanism believed to involve histamine release from airway mast cells and an interaction with neural reflexes. In the present study, we have investigated the effect of oral terfenadine 180 mg, flurbiprofen 100 mg, and the drug combination on AMP-induced bronchoconstriction in eight nonatopic asthmatic subjects with a mean age of 53.8 +/- 5.6 yr. The provocation concentrations of histamine and AMP required to produce a 20% decrease in FEV1 (PC20) were determined to be 2.5 (range, 0.2 to 16.3) and 50.1 (range, 1.5 to 841) mg/ml, respectively, representing a potency difference of 17.8-fold on a molar basis. In subsequent time-course studies, the bronchoconstrictor response to inhalation of the PC20 histamine was suppressed completely by terfenadine and the drug combination, but unaffected by flurbiprofen. Terfenadine alone and flurbiprofen alone inhibited bronchoconstriction provoked by the PC20 AMP by 49.8 +/- 5.5% (p less than 0.01) and 31.9 +/- 7.9% (p less than 0.01), respectively, when areas under the FEV1 time curves were compared with placebo, the difference between the two treatments not being significant (p = 0.06). The drug combination inhibited the response to AMP by 60.0 +/- 8.3% (p less than 0.01), this being significantly greater than with flurbiprofen (p less than 0.01), but not with terfenadine alone. These data implicate both histamine and cyclooxygenase products in the bronchoconstrictor response to AMP. SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/2563320/The_effect_of_oral_terfenadine_alone_and_in_combination_with_flurbiprofen_on_the_bronchoconstrictor_response_to_inhaled_adenosine_5'_monophosphate_in_nonatopic_asthma_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm/139.2.463?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -